Skip to main content
Multiple Sclerosis Discovery Forum
Inspiring Connections
Utility Navigation
Feedback
Newsletter
RSS
Twitter
User Top Menu
Welcome, guest
Log In
Join
Why Join?
Search form
Search
About Us
Overview
Who We Are
Contact
Fan Mail
How to Cite
News & Future Directions
New Findings
News Briefs
Podcasts
News Synthesis
Essays & Opinions
Blogs
Papers
Editors' Picks
Classic Papers
Archive
Forums
Discussions
Webinars
Professional Resources
Meetings & Events
Past Meetings
Funding Opportunities
Jobs
Member Directory
Bulletin Board
Useful Links
Research Resources
Data Visualizations
Clinical Trials - Public Availability of Results
World Map
MS trials baseline
NMO History
NMO Galaxy
Map of MS Prevalence
Progressive MS Authors Galaxy
Word Cloud
MSLine
Ongoing Clinical Trials in MS
MRI-Related Clinical Trials
RRMS and CIS
Immunopathogenesis of MS
The MS Galaxy
ARR in Placebo Groups
Symptoms Prevalence
Scientific Literature TreeMap
Clinical Trials in MS
Drug-Development Pipeline
Tissue Repositories
MSGene
Animal Models
Clinical Trials
Click Here to Support MSDF
You are here
Home
Most Viewed Papers
Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists.
Biogen Idec reports positive top-line results from Phase 2 anti-LINGO-1 trial in people with acute optic neuritis
Vitamin D and disease activity in multiple sclerosis before and during interferon-β treatment.
Granulocyte macrophage colony-stimulating factor: a new putative therapeutic target in multiple sclerosis.
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
IL-17 and Th17 Cells.
Natural recovery and protection from autoimmune encephalomyelitis: contribution of CD4+CD25+ regulatory cells within the central nervous system.
Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis.
The natural history of primary progressive MS in British Columbia, Canada.
FGF2 and FGFR1 signaling regulate functional recovery following cuprizone demyelination.
Regulatory CD4(+) T cells expressing endogenous T cell receptor chains protect myelin basic protein-specific transgenic mice from spontaneous autoimmune encephalomyelitis.
Quantifying the early stages of remyelination following cuprizone-induced demyelination.
An RNA profile identifies two subsets of multiple sclerosis patients differing in disease activity.
Genetics and the environment converge to dysregulate N-glycosylation in multiple sclerosis.
Improving the translational hit of experimental treatments in multiple sclerosis.
TNF alpha promotes proliferation of oligodendrocyte progenitors and remyelination.
Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial.
HLA-DRB1*1501 tagging rs3135388 polymorphism is not associated with neuromyelitis optica.
De- and remyelination in the CNS white and grey matter induced by cuprizone: the old, the new, and the unexpected.
Mycophenolate mofetil for relapsing-remitting multiple sclerosis.
Zist Daru, ZIFERON
Neuroprotection mediated through estrogen receptor-alpha in astrocytes.
Fumaric Acid Esters Do Not Reduce Inflammatory NF-κB/p65 Nuclear Translocation, ICAM-1 Expression and T-Cell Adhesiveness of Human Brain Microvascular Endothelial Cells.
Breast-feeding, postpartum and prepregnancy disease activity in multiple sclerosis.
GlaxoSmithKline Protocol Summaries: Firategrast
Pages
« first
‹ previous
…
14
15
16
17
18
19
20
21
22
…
next ›
last »